Cocrystal Pharma Inc (COCP) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Cocrystal Pharma Inc stock $0.21, price $1.04, that is 79.6% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range $0.8200 – $14.16 · fair‑value band $0.1360 – $0.2635 · the $1.04 price screens above the $0.2125 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Cocrystal Pharma in your weekly email
Every Wednesday you see whether Cocrystal Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
Show moreShow less
The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections.
It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Stock analysis
Cocrystal Pharma Inc (COCP) currently trades at $1.04, while our model-based Fair Value estimate is $0.2125, 80% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.1360 (bear) to $0.2635 (bull), the price of $1.04 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Cocrystal Pharma Inc reported revenue of $0 in FY2025 versus $5.4M in FY2021. Reported net income was −$8.8M in FY2025.
Key figures
Market cap $20.2M Micro · P/S ratio 57.8 · EPS (TTM) $−0.7600 · Return on equity −312% · Return on assets (EBIT) −79.6% (5-year average) · Operating margin −3,032% · Revenue (TTM) $330K · Revenue growth (YoY) +26.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 34% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, COCP screens richer than that median.
Fair Value models
Bear$0.1360Fair Value $0.2125Bull$0.2635
Price $1.04 · Downside -79.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.1600$0.2500$0.310054
All 1 models by family
Asset-Based
NCAV (Graham)$0.1600$0.2500$0.310054
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, one officer or director bought shares worth $80,300, on Aug 5, 2026.
BuyPhillip Md Et Al FrostDirector, 10% owner9× since Nov 25, 2025: 314,000 shares, avg. $0.9571$300,525Aug 5, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−69,164.1% (2015) → −262.0% (2021)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−79.6% · Bottom 25%
Profitability
Return on assets−90.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)26.9% · Top 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B3.20× · Pricier than median
P/S (12 months)61.33× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)92· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cocrystal Pharma Inc (COCP) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $0.2125 versus a price of $1.04, about 80% lower (overvalued).
What is the fair value of COCP?
Our model-based fair value for Cocrystal Pharma Inc is $0.2125 (as of Nov 3, 2026), built from audited fundamentals. The current price: $1.04.
What is the quality score of COCP?
Cocrystal Pharma Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cocrystal Pharma Inc (COCP)?
Our model-based price target is the fair value of $0.2125 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario $0.1360, optimistic scenario $0.2635. It is a calculation from audited fundamentals, not an analyst target.
What is the Cocrystal Pharma Inc stock forecast for 2026?
Our models put fair value at $0.2125, about 80% lower versus a price of $1.04 (overvalued). Cautious scenario $0.1360, optimistic scenario $0.2635. The calculation is refreshed regularly with new filings.
What is the revenue of Cocrystal Pharma Inc (COCP)?
Cocrystal Pharma Inc reported trailing-twelve-month revenue of about $330K (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Cocrystal Pharma Inc (COCP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cocrystal Pharma Inc it is $0.2125 per share (as of Nov 3, 2026), against a price of $1.04. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cocrystal Pharma Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, COCP trades above its calculated fair value: price $1.04, fair value $0.2125, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COCP?
No. The price is what the market pays today ($1.04); the fair value is what the company's own numbers justify ($0.2125). For Cocrystal Pharma Inc the two are $0.8275 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cocrystal Pharma Inc worth?
The market values Cocrystal Pharma Inc at about $20.2M (market capitalisation, as of Nov 3, 2026). Per share that is $1.04; our models calculate a fair value of $0.2125 per share.
What do the bullish and bearish scenarios say about COCP?
Our models span a range for Cocrystal Pharma Inc: cautious scenario $0.1360, base $0.2125, optimistic $0.2635 per share (as of Nov 3, 2026, price $1.04). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cocrystal Pharma Inc (COCP)?
Balance-sheet figures for Cocrystal Pharma Inc (as of Nov 3, 2026): return on equity −311.7%, debt of 0.16 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is COCP from its 52-week high?
Cocrystal Pharma Inc trades at $1.04, about 34% below its 52-week high of $1.57 and 27% above the low of $0.8200 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2125 is for.
Which stocks are comparable to Cocrystal Pharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cocrystal Pharma Inc stock attractive at the current price?
The data as of Nov 3, 2026: price $1.04, calculated fair value $0.2125 (−80%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COCP calculated?
We run Cocrystal Pharma Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.2125 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cocrystal Pharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cocrystal Pharma Inc (COCP)?
The closing price on Nov 6, 2026 was $1.04. Our model-based fair value is $0.2125, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cocrystal Pharma Inc right now?
The price sits above even our optimistic bull case ($0.2635). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1360 to $0.2635) leaves room in how you read the outcome.
Key figures of Cocrystal Pharma Inc
How large is the market capitalisation of Cocrystal Pharma Inc (COCP)?
The market capitalisation of Cocrystal Pharma Inc is $20.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cocrystal Pharma Inc (COCP)?
The price-to-sales ratio of Cocrystal Pharma Inc is 57.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cocrystal Pharma Inc (COCP)?
Earnings per share at Cocrystal Pharma Inc are $−0.7600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cocrystal Pharma Inc (COCP)?
The return on equity (ROE) of Cocrystal Pharma Inc is −312% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cocrystal Pharma Inc (COCP)?
On an EBIT basis the return on assets of Cocrystal Pharma Inc is −79.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cocrystal Pharma Inc (COCP)?
The operating margin of Cocrystal Pharma Inc is −3,032% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cocrystal Pharma Inc (COCP)?
Revenue at Cocrystal Pharma Inc is growing +26.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cocrystal Pharma Inc (COCP) generate?
The free cash flow of Cocrystal Pharma Inc is −$8.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cocrystal Pharma Inc (COCP) hold?
Cocrystal Pharma Inc holds more cash than debt, $5.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Cocrystal Pharma Inc in the live analysis
One click puts Cocrystal Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026
